CELL BASED SCREENING ASSAY TO DETECT NF-KB ACTIVATION

Information

  • Research Project
  • 2713813
  • ApplicationId
    2713813
  • Core Project Number
    R43GM058288
  • Full Project Number
    1R43GM058288-01
  • Serial Number
    58288
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/1998 - 26 years ago
  • Project End Date
    6/30/1999 - 25 years ago
  • Program Officer Name
  • Budget Start Date
    7/1/1998 - 26 years ago
  • Budget End Date
    6/30/1999 - 25 years ago
  • Fiscal Year
    1998
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/6/1998 - 26 years ago

CELL BASED SCREENING ASSAY TO DETECT NF-KB ACTIVATION

DESCRIPTION: This Small Business Innovation Research Phase I project focuses o the development of a two-Transcription factor NF-kB is activated by treatment with a diversity of stimuli, such as TNFa and IL-1b. Its activation leads to expression of an array of biologically important genes whose products contribute to cell growth, apoptosis, inflammation and immune response. Two methods are commonly used to monitor NF-kB activation; one is gel shift assay and the other is transcription induction of a reporter gene. Both of assays ar not suitable for high throughput drug screening because they are either time consuming or tedious. The proposal of this study is to develop a cell-based HT screening assay to detect NF-kB activation by monitoring IkB (degradation via its fusion with enhanced green fluorescent protein (EGFP). Our previous study indicates that EGFP can be converted from a stable protein into destablized by fusing with a degradation domain and can be used as a reporter for monitoring protein degradation. In this study, we propose to use EGFP to monitor IkB (degradation by making a fusion protein of these two proteins. Change of the fluorescence intensity of EGFP is expected to coordinate to the degradation of IkB( protein. Because IkB (degradation occurs within minutes after the treatment and EGFP detection is simple, this method will provide a quick and easy assay that allows to detect NF- kB activation. This technology will facilitate the discovery of potential drugs that can either stimulate or inhibit the process of NF-kB activation. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG3
  • Study Section Name
  • Organization Name
    CLONTECH LABORATORIES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    PALO ALTO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94303
  • Organization District
    UNITED STATES